Observational studyMuscle & nerve2026
Electrophysiological Changes in Pediatric Spinal Muscular Atrophy: Results From an Observational Study.
Observational study in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions.Nature reviews. Neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
INTRODUCTION/
aimsPrevious studies of children with spinal muscular atrophy (SMA) have focused on the ulnar and median nerves, while lower-limb and proximal motor nerves remain insufficiently characterized. This study aimed to evaluate compound muscle action potential (CMAP) amplitudes in upper- and lower-limb motor nerves in children with SMA and changes after nusinersen treatment.
methodsIn this single-center retrospective study, CMAP amplitudes were collected from children with SMA and age-matched controls without neuromuscular disease. CMAP amplitudes of the tibial, peroneal, femoral, median, and ulnar nerves were assessed in children with SMA types 1-3. A cross-sectional analysis was conducted to assess CMAP amplitudes prior to treatment. Longitudinal changes after SMA disease-modifying therapies (nusinersen monotherapy or nusinersen plus risdiplam treatment) were evaluated.
resultsA total of 47 children with SMA were included. The baseline CMAP amplitudes of the peroneal, tibial, median, and ulnar nerves were the highest in type 3, followed by type 2, and lowest in type 1. Femoral nerve CMAP amplitudes were low in all SMA subtypes. At preliminary diagnosis, children with SMA had significantly reduced CMAP amplitudes for the five nerves compared with age-matched controls (n = 63, p < 0.05). After 18 months of nusinersen treatment, CMAP amplitudes showed significant increases from baseline in the peroneal, femoral, median, and ulnar nerves (p < 0.05). DISCUSSION: CMAP amplitudes can differentiate SMA disease severity and may increase after nusinersen treatment. Large-scale longitudinal studies are required to investigate CMAP amplitude as a biomarker of treatment response in patients with SMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.